Abstracts tagged "psoriatic arthritis and quality of life"

Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
Abstract Number: 654 • 2015 ACR/ARHP Annual Meeting
Associations Between Skin Outcomes By Body Area Affected and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Alice B. Gottlieb¹, Bengt Hoepken², Luke Peterson³ and Peter C. Taylor⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²UCB Pharma, Monheim, Germany, ³UCB Pharma, Raleigh, NC, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) report poorer health-related quality of life (HRQoL) compared to the general population. As with psoriasis (PSO), it is…
Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Kiana Vakil-Gilani¹, Alexis Dinno², Neha Garg³ and Atul A. Deodhar⁴, ¹Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ²School of Community Health, Portland State University, Portland, OR, ³Rheumatology, Oregon Health and Science University, Portland, OR, ⁴Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…
Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition
Ana-Maria Orbai^1,2, Suzanne Grieb³, Clifton Bingham⁴, Michelle Jones⁴, Grazyna Purwin⁵ and Katherine Clegg-Smith⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Arthritis Center, Baltimore, MD, ⁶Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…
Abstract Number: 1548 • 2014 ACR/ARHP Annual Meeting
Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial
Christopher T. Ritchlin¹, Proton Rahman², Lluís Puig Sanz³, Alice B. Gottlieb⁴, Arthur Kavanaugh⁵, Iain B. McInnes⁶, Shu Li⁷, Yuhua Wang⁷, Rita Ganguly⁸, Alan M. Mendelsohn⁹ and Chenglong Han⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Tufts Medical Center, Boston, MA, ⁵University of California San Diego, La Jolla, CA, ⁶Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the treatment effect of ustekinumab on fatigue using data from PSUMMIT 2. Methods: Adult patients with active psoriatic arthritis (PsA) despite DMARD…
Abstract Number: 1557 • 2013 ACR/ARHP Annual Meeting
Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction
M. Elaine Husni¹, Daniel Duch² and Neil J. Korman³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Curatio CME Institute, Exton, PA, ³Case Western Reserve Univ (Uni, University Hospitals Dermatolo, Cleveland, OH
Background/Purpose: Despite the availability of more targeted therapies for psoriatic arthritis (PsA), an assessment of the impact these have had on patient well-being has not recently…
Abstract Number: 995 • 2013 ACR/ARHP Annual Meeting
Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Psoriatic Arthritis Patients In The Czech Republic
Jiri Stolfa^1,2, Liliana Sedova^1,2, David Suchy³, Jiri Klimes⁴, Milan Vocelka⁴ and Tomas Dolezal⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, ³Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, ⁴Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic
Background/Purpose: Our aim was to describe the QoL, productivity impairment, clinical indicators and health care costs in relationship to functional status described by Health assessment…
Abstract Number: 322 • 2013 ACR/ARHP Annual Meeting
Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials
Proton Rahman¹, Lluis Puig², Alice B. Gottlieb³, Arthur Kavanaugh⁴, Iain B. McInnes⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Ning Zhao⁸, Rita Ganguly⁸, Michael Song⁷, Alan M. Mendelsohn⁹ and Chenglong Han⁸, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴University of California, San Diego, La Jolla, CA, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To examine the impact of ustekinumab (UST) treatment on patient reported outcomes in patients with active psoriatic arthritis (PsA) using week 24 data from…
Abstract Number: 329 • 2013 ACR/ARHP Annual Meeting
Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Lars Törnqvist¹, Tomas Husmark², Ulla R. C. Lindqvist³, Gerd-Marie Alenius⁴, Per Larsson⁵, Annika Teleman⁶, Mats Geijer⁷, Lars Erik Kristensen⁸, Ingrid Thyberg⁹ and Elke Theander¹⁰, ¹Department of Rheumatology, Skåne University Hospital Malmö, Lund University, Sweden, Malmö, Sweden, ²Department of Rheumatology, Falu Hospital, Falun, Sweden, ³Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Rheumatology, Linköping University Hospital, Linkoping, Sweden, ¹⁰Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Studies on early psoriatic arthritis (ePsA) are still rare and data on health related quality of life (HRQoL) in ePsA are lacking completely. To…
Abstract Number: 1828 • 2012 ACR/ARHP Annual Meeting
Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis
Ann B. I. Bremander¹, Lennart TH Jacobsson², Stefan Bergman³, Emma Haglund⁴ and Ingemar F. Petersson⁵, ¹Department of Exercise Physiology, Biomechanics and Health, Halmstad University School of Business and Engineering, Halmstad, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Spenshult Research and Development Center, Halmstad, Sweden, ⁴Research and Development Centre, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden, ⁵Lund University, Lund, Sweden
Background/Purpose: Smoking has been found to be associated with an increased risk of developing psoriatic arthritis (PsA). The purpose of this study was analyse possible…
Abstract Number: 540 • 2012 ACR/ARHP Annual Meeting
The Predictors of Reduced Work Productivity in Patients with Psoriatic Arthritis
Anjali Papneja¹, Matthew Kennedy², Arane Thavaneswaran³, Daniel Pereira⁴, Vinod Chandran⁵ and Dafna D. Gladman⁶, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Toronto, TOronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory musculoskeletal disorder associated with psoriasis. Related to its detrimental impact on health and quality of life, PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].